Dicerna
The delivery approach has gained traction in recent years and is being explored by a number of RNA drug firms.
Dicerna's new RNAi triggers and conjugate technology are entirely proprietary and fall outside of intellectual property held by other organizations, according to a company official.
NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals last week reported its third-quarter financial results, posting higher losses amid increased spending on its drug-development programs.
Dicerna's net loss for the period rose to $11.2 million from $4.5 million the year before.
NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals this month confirmed previous guidance on its two drug candidates, the solid tumor therapy DCR-MYC and the primary hyperoxaluria 1 (PH1) treatment DCR-PH1, stating that both agents remain on track to enter new clinical trials later this year and in 2
NEW YORK (GenomeWeb) – With more interest from industry and investors than ever before, the RNAi therapeutics field has a record number of drug candidates in human testing for indications ranging from viral disease to cancer to skin disorders.
Jul 3, 2014
May 15, 2014
Apr 24, 2014
Apr 17, 2014
Apr 3, 2014
Feb 13, 2014
Jan 30, 2014
Jan 9, 2014
Jan 2, 2014
Dicerna Files for $69M IPO
Premium
Oct 10, 2013
Aug 8, 2013
Aug 1, 2013
Apr 11, 2013
Apr 4, 2013
Jan 3, 2013